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REQUESTED COMMENT 
Tirone E. David, MD, Toronto, Ontario, Canada 
The concerns of Dr. Gallo and associates regarding out 
technique of reconstruction of the aortic root with pres- 
ervation of the aortic valve are valid. We also expressed 
concerns about it in our original article. 1 However, we 
have now preserved the aortic valve in more than 50 
patients with aortic root aneurysm and we have had only 
one late failure, which occurred in a teenager with 
Marfan's syndrome. 2 The aortic valve function has re- 
mained stable up to 5 years in the remaining patients. 
Patient selection is probably the single most important 
factor in the outcome of any valve repair. In patients with 
aortic root aneurysm the aortic valve should be repaired 
only when the leaflets are normal. In a normal eaflet the 
length of its base is approximately 1.5 times longer than 
the length of its free margin. Next, if the patient has severe 
aortic valve insufficiency, the cause of valve dysfunction 
must be determined and the appropriate surgical tech- 
nique used. When there is enlargement of both the 
aortoventricular junction and the sinotubular junction, an 
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aortic annuloplasty and resuspension of the leaflets in a 
Dacron fabric tube is necessary (we refer to this technique 
as "reimplantation of the aortic valve"). When only the 
sinotubular junction is enlarged, supraannular reconstruc- 
tion of the aortic root with or without reimplantation of 
the coronary arteries is done (we refer to this technique as 
"remodeling of the aortic root"). 2 
By using these techniques in carefully selected patients 
we have been able to provide excellent clinical results in 
51 of 53 patients operated on during the past 5 years. 
We remain carefully optimistic about these operative 
techniques. Observations uch as those of Gallo and 
colleagues are important as surgeons introduce new op- 
erative techniques and they stress the necessity of continu- 
ing follow-up of these patients. 
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LIDOFLAZINE AND MYOCARDIAL PROTECTION 
B. Akpinar, MD,* H. Vanerman, MD, and F. Wellens, MD, Aalst, Belgium 
Lately interest in the myocardial protective ffects of 
lidofiazine (Janssen Research Foundation, Beerse, Bel- 
gium) has been renewed. Although many clinical and 
experimental studies on this drug have been conducted, 
the mechanism of its cardioprotective effect has not been 
completely established. Selective calcium entry blocking 
activity of the drug was not demonstrated, but the latest 
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studies focus more on the nucleoside transport inhibitory 
effect of lidoflazine. 1'2 
For more than a decade, we have been using lidoflazine 
pretreatment, moderate hypothermia, nd a single period 
of crossclamping for coronary artery operations, with 
excellent results. We wanted to make a comparative study 
to evaluate the myocardial protective ffect of lidoflazine 
using hemodynamic, biochemical, and clinical parameters. 
Fifty patients, 25 in each group, were selected according 
to their age, sex, and left ventricular ejection fraction. 
Patients older than 70 years of age, patients with com- 
bined procedures or reoperations, and patients with an 
impending myocardial infarction were excluded from the 
study. Left ventricular ejection fraction less than 30% was 
also an exclusion criteria. Data on both groups A and B 
are shown in Table I. 
In group A, in which lidofiazine and a single crossclamp 
